drugset / Trial / NCT00014430
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
Phase 1
Completed
13 enrolled
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of vinorelbine plus trastuzumab in treating patients who have refractory or metastatic breast cancer.
Timeline
- Start
- 1999-11
- Primary completion
- 2002-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Vinorelbine | Small molecule | — | Intravenous |